In its release on
-Cash Position: Cash and cash equivalents as of
-Revenues: Revenues were
-R&D Expenses: Research and development expenses were
-Other Operating Expenses: Other operating expenses totaled
-Net Income (Loss): Net income was
-Collaborations and KLH Supply Agreements: Stellar KLH is currently used by the Company's biopharma partners as the carrier molecule in certain new immunotherapies in clinical development for cancer, autoimmune disease and inflammatory disease. Those programs continued to progress in 2014 and Stellar met all contract requirements related to supply and/or development of KLH protein for those product candidates. In addition, Stellar continues to strengthen its collaboration expansion with biopharma companies as their immunotherapy programs advance in the clinic to later stages of development and potential regulatory submissions. These strategic collaborations represent multiple commercial pathways for Stellar including future growth of core business sales and close involvement in the development of new KLH-based immunotherapies.
-C. diff Active Immunotherapy Program:: During the first half of 2014, Stellar successfully advanced its C. diff active immunotherapy program in key preclinical areas including early process development and the scale-up and transfer of essential manufacturing methods to a contract manufacturing organization (CMO). The goal of this stage of product development is to establish scalable processes necessary to support GMP production of a PS-KLH conjugate vaccine candidate. In the second half of 2014, the Company will focus on completing certain IND-enabling milestones such as identification of appropriate PS-KLH formulation, demonstration of dose ranging and safety, intermediary scale-up and manufacturing of test material in preparation for clinical production.
"This has been an important strategic year for Stellar and we are pleased to report positive momentum in key facets of our KLH business," said
More information and complete details:
((Comments on this story may be sent to firstname.lastname@example.org))
In its release on